seh

Dual FAAH sEH-IN-1 is a dual inhibitor of sEH (soluble epoxide hydrolase) (IC50: 9.6 nM) and FAAH (fatty acid amide hydrolase) (IC50: 7 nM) with high affinity and anti-inflammatory activity.

sEH inhibitor-7 is a soluble epoxide hydrolase (sEH) inhibitor that inhibits sEH in human and mouse with IC 50 s of 6.2 μM and 0.15 μM, respectively. sEH inhibitor-7 is associated with anti-inflammatory active molecules.

sEH inhibitor-1 (compound TCPU) is a potent, orally active inhibitor of soluble epoxide hydrolase (sEH) with IC50 values of 0.4 and 5.3 nM for human and murine she, respectively.

sEH AChE-IN-3 (15) serves as a dual inhibitor targeting both soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), demonstrating potent activity and the ability to cross the blood-brain barrier (BBB). It exhibits IC50 values of 0.4 nM for human sEH (hsEH), 1.94 nM for human AChE (hAChE), 615 nM for human butyrylcholinesterase (hBChE), 4.3 nM for mouse sEH (msEH), and 2.61 nM for mouse AChE (mAChE), indicating its efficacy across these enzymes.

sEH Inhibitor-16, a potent soluble epoxide hydrolase (sEH) inhibitor, exhibits an IC50 of 2 nM. It diminishes inflammatory damage associated with cerulein-induced acute pancreatitis (AP) in mice, making it suitable for inflammation and immunology research [1].

VU534 is a NAPE-PLD agonist with an EC50 of 0.30 μM.VU534 is a dual inhibitor of FAAH and sEH, with an IC50 of 1.2 μM for sEH.VU534 is used in diseases related to cardiometabolism.

sEH inhibitor-17 (compound 4f) is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC50 value of 2.94 nM. This compound exhibits anti-inflammatory properties.

beta-Amyrin acetate inhibits HMG-CoA Reductase (HMGCR) and sEH activity with IC50 of 3.4 μM. beta-Amyrin acetate has anti-inflammatory, antifungal, antioxidant, and anti-hyperlipidemic activities.

sEH AChE-IN-4 -15 is a potent, blood-brain barrier-penetrating dual inhibitor targeting soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). It demonstrates notable inhibition efficacy, with IC50 values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), indicating its significant inhibitory action across both targeted enzymes in human and mouse models.

sEH AChE-IN-2 and acetylcholinesterase ( AChE ). sEH AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH AChE-IN-2 has the potential for the research of Alzheimer's disease (AD) .

sEH inhibitor-5 is a potent inhibitor of sEH (soluble epoxide hydrolase) (IC50: 0.1 nM).

sEH inhibitor-4 (compound B15) has been identified as a potent soluble epoxide hydrolase (SEH) inhibitor with a remarkable inhibitory potency of 0.03 ± 0.01 nm. Intensive structural modification efforts led to the discovery of this compound for its ability to decrease inflammation and alleviate pain in the presence of SEH.

sEH AChE-IN-1 (Compound 12a) is a dual inhibitor of soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE) with potential research applications in Alzheimer's disease (AD) due to its cumulative effect against neuroinflammation and memory impairment.

SEH inhibitor-2 (compound 5l) is a soluble epoxide hydrolase (sEH) inhibitor with oral activity (IC50=0.9 nM), and the predicted oral absorption percentage is 71.2-88.4%. SEH inhibitor-2 can maintain a high concentration of eicosanoic acid (EETs) in serum. SEH inhibitor-2 has research value in cardiovascular protection.

sEH-IN-12 is an effective inhibitor of the enzyme soluble epoxide hydrolase (sEH).

sEH-IN-1 (example 67), an inhibitor of soluble epoxide hydrolase (sEH), is utilized in studying diseases mediated by sEH, including hypertension, cardiovascular disease, inflammation, and diabetes [1].

Compound 8o (5-LOX sEH-IN-1) is a dual inhibitor with cardioprotective properties, targeting both 5-LOX and sEH with IC50 values of 3.05 μM and 2.20 nM respectively. It also inhibits the activity of COX-2 (IC50=10.50 μM). Possessing analgesic and anti-inflammatory properties, 5-LOX sEH-IN-1 reduces ulcerogenicity, making it a potential candidate for developing anti-inflammatory agents with fewer gastrointestinal and cardiovascular side effects.

sEH-degrader-1 (Compound 8) acts as an effective inhibitor of sEH, exhibiting IC50 values of 3.8 nM for hsEH and 210 nM for msEH. Additionally, it proficiently degrades sEH in both mouse liver and brown adipose tissue.

sEH FLAP-IN-1 (Compound 46A) serves as a dual inhibitor targeting both sEH and FLAP, effectively suppressing 5-LOX product formation with an EC50 of 11 nM in SACM-stimulated PBMCs, inhibiting sEH activity (EC50: 18 nM), and reducing thromboxane production. This compound is utilized in the study of inflammatory diseases [1].

COX-2 sEH-IN-1 is an orally active dual inhibitor of COX-2 (IC50: 1.24 μM) and sEH (IC50: 0.40 μM), a soluble epoxide hydrolase. COX-2 sEH-IN-1 increases anti-inflammatory effects and significantly reduces cardiovascular risk.

mPGES-1 sEH-IN-1 (compound 1f) is an sEH inhibitor with an IC50 value of 5 μM. It also exhibits antitumor activity by inhibiting mPGES-1, with an IC50 value of 25 µM.

sEH inhibitor-3 (compound 35) is a potent, orally active inhibitor of soluble epoxide hydrolase (sEH), acting on human sEH with a Ki of 0.75 nM.

sEH HDAC6-IN-2 is an effective dual inhibitor of soluble epoxide hydrolase (sEH) and HDAC6, demonstrating IC50 values of 0.9 nM for human sEH, 46.8 nM for mouse sEH, and 8 nM for HDAC6. It is used in research focused on inflammatory pain.

sEH HDAC6-IN-1 (compound M9) serves as a selective, orally active dual inhibitor targeting both sEH and HDAC6. It demonstrates IC50 values of 2 nM for human sEH, 0.72 nM for murine sEH, and 5 nM for HDAC6. Notably, sEH HDAC6-IN-1 exhibits analgesic and anti-inflammatory effects [1].